(Reuters) -German vaccine maker BioNTech said on Tuesday that it plans to expand its investment in the United Kingdom by up ...

German biopharma company BioNTech has said it will commit up to £1 billion ($1.34 billion) in investment in the UK over the ...

Government signs deal to see huge investment in mRNA vaccine manufacturing which could help tackle the next pandemic and ...

Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a ...

Cambridge is set to become home to a major new research and development hub as part of a £1bn UK investment by biopharmaceutical firm BioNTech, expected to create more than 400 ...

BioNTech announced on Tuesday that it will invest up to £1bn over the next decade to expand its research and development ...

German vaccine pioneer BioNTech (Nasdaq: BNTX) today revealed that its UK subsidiary has signed a grant agreement with the UK ...

A "landmark" investment of up to £1billion in the British life sciences sector will turbocharge drug discovery and research ...

BioNTech said it plans to invest up to 1 billion pounds ($1.34 billion) over the next 10 years to expand its research and development activities for innovative medicines in the U.K.

Shares of Vaccine stocks are moving higher on Tuesday after documents from the U.S. Food and Drug Administration revealed ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

BioNTech’s investment provides a template for UK growth, say ABPI The innovative biopharmaceutical company BioNTech has announced a major investment of up to £1bn over 10 years in the UK, potentially ...